To our knowledge, MA4-hFc-CD16AM19 is the first CD16A/GPC3 BsAb optimized for HCC, combining species-specific NK cell activation with Fc engineering to minimize off-target effects. This evidence concerns the gene GPC3 and hepatocellular carcinoma.